Stay tuned
Valsartan mess to spawn the latest surge of drug injury lawsuits: Bloomberg
As the FDA and other drug agencies work to contain the damage from a
Kite's CAR-T manufacturing gets another boost with new Maryland facility
With an FDA approval for its pricey CAR-T therapy Yescarta under its
Overwhelmed by Shingrix demand, GSK plots $100M vaccine manufacturing boost
After supply constraints hindered Shingrix's launch last year, GSK is
Drug distributor and 2 of its executives hammered with felony criminal charges for opioid sales
In a new attack on the pharmaceutical industry’s involvement in opi
Still reeling from aducanumab flop, Biogen executives lay their cards on the table
Biogen suffered a major trial failure in Alzheimer's disease last mon
Stay tuned
© 1994 - 2019 B.M. Pharmaceuticals